Please ensure Javascript is enabled for purposes of website accessibility

Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March

By Cory Renauer - Apr 11, 2016 at 11:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This stock is as prone to soaring (and diving) as its name suggests.

Image source: Raptor Pharmaceuticals Corp.

What: Shares of Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), a biopharmaceutical focused on treating rare diseases, rose 25% last month, according to data from S&P Global Market Intelligence.

RPTP Chart

So what: An announcement mid-month that the FDA would expedite the review of inhaled antibiotic Quinsair gave the stock a solid boost. The main ingredient, levofloxacin, is decades-old, but this would be the first inhaled version for adults with cystic fibrosis.

A week later, Canadian regulators accepted an application for Raptor's only commercial-stage product, Procysbi. That bolstered the previous week's gains, which continued into April as reported rumors of a potential sale led to a 20% spike in minutes.

Lack of official comment is quickly deflating that balloon, but the stock is as prone to soaring, and diving, as its name suggests. Last year, its shares fell 40% in a day, after Procybsci failed a nonalcoholic steatohepatitis trial that would have expanded its label.

Now what: At present, Raptor's only commercial-stage product is Procysbi, also known as RP103. It's a specially coated version of a drug first approved in 1994, cysteamine bitartrate, for treatment of children with an ultra-rare metabolic disease called nephropathic cystinosis.

Steady doses of cysteamine bitartrate allow them to lead relatively normal lives. Mylan began marketing a pill form in 1995, but the trouble is, it required dosing every six hours. Raptor's contribution is an enteric coating that resists stomach acid and then dissolves more slowly in the small intestine, allowing dosing every 12 hours.

Image source: Raptor Pharmaceuticals Corp.

Enteric coatings are even older than cysteamine bitartrate, but with fewer than 500 U.S. patients suffering from nephropathic cystinosis, their plight went unnoticed until Raptor won approval and, more incredibly, reimbursement, for Procysbi. Mylan's six-hour version costs about $140 for 400 50 mg pills, but U.S. commercial insurers reimburse Raptor at a rate of $17,812.50 per bottle of 250 75-mg capsules. The recommended maintenance dosage for a 50-pound child is eight of those pills, twice a day, costing insurers over $416,000 per year. 

In the E.U., reimbursement rates are far lower, and I don't expect Health Canada to pay such a large price, either. This means the impressive revenue growth we've seen from Procysbi will probably level off soon.

I would never have dreamed Procysbi would earn reimbursement at a rate that makes it one of the world's most expensive medicines, given its limited contribution to medical science. 

Who knows what kind of reimbursement rates it can secure for its inhaled version of a decades-old antibiotic, Quinsair. For the sake of Raptor's shareholders, I hope it's equally stunning. Running clinical trials for a simple cystine reducer in nonalcoholic steatohepatitis, Huntington's disease, and mitochondrial diseases isn't cheap.

As a result, Raptor has yet to produce a profit. If increasing scrutiny of pricey specialty drugs impedes its ability to charge a king's ransom for decades-old drugs with new-ish delivery methods, it never will.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.